Glycoprotein IIb/IIIa receptor inhibitors in XXXX and @entity1187 .

@entity1 @entity1187 @entity301 @entity6541 @entity1459 @entity583
OBJECTIVE: To review the contemporary role of the glycoprotein (GYP) IIb/IIIa receptor inhibitors abciximab, eptifibatide, and @entity6541 in @entity1 undergoing @entity301 ( @entity301 ) and those with an @entity1187 ( @entity1187 ), and to provide an algorithm based on currently available evidence for specific agents. DATA SOURCES: Primary articles were identified by a MEDLINE search (1966-January 2003); references cited in these articles provided additional resources. STUDY SELECTION AND DATA EXTRACTION: All of the articles identified from data sources were considered for relevant information; this article primarily addresses large, controlled or comparative studies, and meta-analyses. DATA SYNTHESIS: The role of GYP IIb/IIIa inhibitors in @entity1 undergoing @entity301 and those with @entity1187 has progressed markedly. To date, abciximab has the most robust data in @entity1 undergoing @entity301 , particularly high-risk individuals. In @entity301 @entity1 with lower risk (e.g., elective stenting), eptifibatide is a reasonable first-line option. Data do not support @entity6541 for routine use in @entity1 undergoing @entity301 . For individuals with signs and symptoms of @entity1187 , specifically @entity1459 or non-ST-segment elevation @entity583 ( @entity583 ), eptifibatide or @entity6541 is recommended in high-risk @entity1 when a conservative approach is used ( @entity301 is not planned). Abciximab is not recommended in this situation. In @entity1 with ST-segment elevation @entity583 (STEMI), abciximab is the only GYP IIb/IIIa inhibitor evaluated in large, well-designed investigations. For medical management in combination with a fibrinolytic agent, the role of abciximab remains unclear. For @entity1 undergoing primary @entity301 for the management of STEMI, the available evidence supports the use of abciximab, albeit further investigation is warranted. CONCLUSIONS: The role of GYP IIb/IIIa inhibitors in clinical cardiology continues to evolve. Choice of the agent depends on situation of use, @entity1 -specific characteristics and risk stratification, and, in the case of @entity1187 , chosen management strategy (medical management or intervention).
